Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-217 Neoadjuvant Therapy in Resectable Stage III Melanoma
NCT05751928Phase 3Active, not recruiting
- Sponsor
- BIOCAD
- Start
- Apr 2023
- Primary completion
- Jan 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of BCD-217 in cutaneous melanoma (CM), sponsored by BIOCAD. Started Apr 2023; status: active, not recruiting.
02
Drugs
BCD-217
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT05751928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751928.